First Author: I.Chatziralli GREECE
Co Author(s): A. Agorastos M. Charalambidis Z. Migkos P. Dimitriadis M. Moschos P. Kiryttopoulos 0 0 0 0 0 0 0 0 0
Back to previous
It is well-established that diabetes mellitus (DM) increases oxidative stress, which plays a key regulatory role in the development of its complications, such as diabetic retinopathy (DR), one of the main causes of visual loss. To investigate the association between oxidative stress, as expressed by serum malondialdehyde (MDA), and the stage of DR, as well as gender.
1Laboratory of Electrophysiology, 1st Department of Ophthalmology, University of Athens, Athens, Greece 2Department of Oncology, Specialized Anticancer Hospital “Theageneio”, Thessaloniki, Greece 3Department of Internal Medicine, General Hospital of Veroia, Veroia, Greece
282 insulin-dependent type II diabetic patients, 138 male and 144 female, aged between 50-70 years, participated in the study. Patients included in the study presented cardiac failure stage I (according to NYHA) without myocardial infarction history and/or kidney failure stage I without diabetic nephropathy. Female patients are post menopause and smokers were excluded. All patients received furosemide, statin and MEA inhibitors or Angiotensin inhibitors, but no anti-oxidants. All participants presented DR at any stage, according to the International Clinical Diabetic Retinopathy guidelines, with HbA1C less than 7.5 g/dl. Spectrophotometric detection of MDA from serum was performed. The association between serum MDA levels (nmol/ml) and DR stage, as well as gender was examined. Univariate analysis was performed using SPSS 20.0 statistical software. Significance was defined as p<0.05.
Serum MDA was positively associated with DR stage (Spearman’s rho=+0.902, p<0.0001). A borderline association was found regarding the association between serum MDA and gender (p=0.057, Mann-Whitney-Wilcoxon test).
Our study implies that oxidative stress is highly associated with severe DR, suggesting MDA as a biomarker in monitoring the severity of DR in insulin-dependent type II diabetic patients.